title: MicroRNA-219 modulates NMDA receptor-mediated neurobehavioral dysfunction.
abstract: N-methyl-D-aspartate (NMDA) glutamate receptors are regulators of fast neurotransmission and synaptic plasticity in the brain. Disruption of NMDA-mediated glutamate signaling has been linked to behavioral deficits displayed in psychiatric disorders such as schizophrenia. Recently, noncoding RNA molecules such as microRNAs (miRNAs) have emerged as critical regulators of neuronal functions. Here we show that pharmacological (dizocilpine) or genetic (NR1 hypomorphism) disruption of NMDA receptor signaling reduces levels of a brain-specific miRNA, miR-219, in the prefrontal cortex (PFC) of mice. Consistent with a role for miR-219 in NMDA receptor signaling, we identify calcium/calmodulin-dependent protein kinase II gamma subunit (CaMKIIgamma), a component of the NMDA receptor signaling cascade, as a target of miR-219. In vivo inhibition of miR-219 by specific antimiR in the murine brain significantly modulated behavioral responses associated with disrupted NMDA receptor transmission. Furthermore, pretreatment with the antipsychotic drugs haloperidol and clozapine prevented dizocilpine-induced effects on miR-219. Taken together, these data support an integral role for miR-219 in the expression of behavioral aberrations associated with NMDA receptor hypofunction.
authors.affiliation: Department of Molecular and Integrative Neurosciences, The Scripps Research Institute, 130 Scripps Way, Jupiter, FL 33458, USA.
authors.forename: Jannet
authors.initials: J
authors.lastname: Kocerha
authors.forename: Mohammad Ali
authors.initials: MA
authors.lastname: Faghihi
authors.forename: Miguel A
authors.initials: MA
authors.lastname: Lopez-Toledano
authors.forename: Jia
authors.initials: J
authors.lastname: Huang
authors.forename: Amy J
authors.initials: AJ
authors.lastname: Ramsey
authors.forename: Marc G
authors.initials: MG
authors.lastname: Caron
authors.forename: Nicole
authors.initials: N
authors.lastname: Sales
authors.forename: David
authors.initials: D
authors.lastname: Willoughby
authors.forename: Joacim
authors.initials: J
authors.lastname: Elmen
authors.forename: Henrik F
authors.initials: HF
authors.lastname: Hansen
authors.forename: Henrik
authors.initials: H
authors.lastname: Orum
authors.forename: Sakari
authors.initials: S
authors.lastname: Kauppinen
authors.forename: Paul J
authors.initials: PJ
authors.lastname: Kenny
authors.forename: Claes
authors.initials: C
authors.lastname: Wahlestedt
mesh_terms: D000818:Animals; D001522:Behavior, Animal / Q000187:drug effects; D001692:Biological Transport; D054732:Calcium-Calmodulin-Dependent Protein Kinase Type 2 / Q000378:metabolism; D045744:Cell Line, Tumor; D016291:Dizocilpine Maleate / Q000494:pharmacology; D005786:Gene Expression Regulation; D015316:Genetic Therapy; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D035683:MicroRNAs / Q000235:genetics* / Q000627:therapeutic use*; D009422:Nervous System Diseases / Q000235:genetics* / Q000378:metabolism* / Q000503:physiopathology / Q000628:therapy; D021122:Protein Subunits / Q000378:metabolism; D012333:RNA, Messenger / Q000235:genetics / Q000378:metabolism; D016194:Receptors, N-Methyl-D-Aspartate / Q000235:genetics / Q000378:metabolism*; D015398:Signal Transduction
chemical_list: D035683:MicroRNAs; D021122:Protein Subunits; D012333:RNA, Messenger; D016194:Receptors, N-Methyl-D-Aspartate; D016291:Dizocilpine Maleate; D054732:Calcium-Calmodulin-Dependent Protein Kinase Type 2